Company: BLUWU
Filing Date: 2025-03-31
Form Type: S-1/A
Source: 0001641172-25-001410
Chunk: 203

Company: Blue Water Acquisition Corp. III
Filing Date: 2025-03-31
Form: S-1/A
Chunk 203
---
ropic, Scale AI, Groq, Digital Ocean (NYSE: DOCN), Rubrik (NYSE: RBRK), Robinhood (Nasdaq: HOOD), and many others. Previously, Mr. Dugal was an Investment Director at a large European asset management firm. Earlier, he was an Associate at Paladin Capital Group, a multi-stage PE/VC firm. Mr. Dugal holds an MBA from The Wharton School – University of Pennsylvania and a B.S. with High Honors from the University of Maryland, College Park.

Laurent D. Hermouetwill serve as a member of our board of directors upon the effectiveness of the registration statement of which this prospectus forms a part. Mr. Hermouet is a Partner at Athyrium Capital Management LP, an asset management company focused on investment opportunities in the broader healthcare and life sciences sectors encompassing biotechnology, pharmaceuticals, healthcare services, healthcare technology and medical devices and products. With over two decades of experience, Mr. Hermouet has completed more than two dozens of transactions in the biotech, pharma, medtech, and pharma services sectors in both North America and Western Europe. Working closely with senior management and board members, Mr. Hermouet focuses on growth and related financing. Prior to joining Athyrium, Mr. Hermouet was a senior credit analyst at Tribeca Investments, a Citigroup-backed multi-strategy hedge fund, and a credit analyst at Goldman, Sachs & Co. Mr. Hermouet is a CFA Charterholder. Mr. Hermouet holds a bachelor degree in economics as well as a master degree in finance from University Paris Dauphine.

| 135 |

Prior Experience with Blank Check Companies

Our management team and board members possess experience in sponsoring and operating blank check companies, having served on the board or on the management team of various blank check companies as follows:

Blue Water Acquisition Corp. completed its initial public offering in December 2020 and consummated its business combination with Clarus Therapeutics Inc., a pharmaceutical company, in September 2021, in connection with which approximately 57% of the public shares were redeemed. Joseph Hernandez served as the chairman and chief executive officer of Blue Water I from May 2020 to September 2021. Mr. Hernandez served as a director of the post-combination entity, Clarus Therapeutics Holdings Inc., until August 2022. In September 2022, Clarus Therapeutics Holdings Inc. and Clarus Therapeutics Inc